TAKEDA Aktie

 

TOKYO (dpa-AFX) - Japan's Takeda Pharmaceutical Co. Ltd. (TAK,4502.T) announced Monday positive new data from VERDICT (NCT04259138), a Phase 4 ENTYVIO clinical trial, in ulcerative colitis or UC-r......

A model for private sector–nonprofit collaboration in tackling life-threatening health risksWASHINGTON & TOKYO--(BUSINESS WIRE)--Corus International announced it has received a $6.4 million grant from Takeda Pharmaceutical Company Limited to help reduce climate-related health risks in Nepal. Corus was selected as part of Takeda's 2026 Global Corporate Social Responsibility (CSR) program. The company issued a press release announcing all the awardees and the scope of its program. Corus is a leading global non-governmental humanitarian assistance and development organization based in Washington, D.C. The grant provides Corus with five years of support for a first-of-its-kind initiative to help communities in Nepal anticipate and respond to climate-related health threats before they become crises. Corus International President and CEO Ambassador Daniel Speckhard said, “This innovative program shows what's possible when the private sector and nonprofits come together to solve some of the world's most c...

TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Ltd. (TAK,4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque......

LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis (“MF”) and anemia on concurrent ruxolitinib therapy....

Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche's Annual General Meeting on March 9, 2027....

Der Verwaltungsrat der Roche Holding AG hat beschlossen, Herrn Dr. Christophe Weber, ehemaliger CEO von Takeda Pharmaceuticals, der Generalversammlung am 9. März 2027 zur Neuwahl in den Verwaltungsrat vorzuschlagen....

Oriola will start distributing Takeda's product portfolio in Finland from 1 October, expanding the long-standing Nordic partnership between the companies. The agreement reflects Takeda's confidence in Oriola's customer-centric way of working and ability to combine operational quality with flexibility and close collaboration. Takeda is one of the world's leading pharmaceutical companies and a strategic customer for Oriola. Oriola has distributed Takeda's products in Sweden for more than 10 years, and the companies have also collaborated through Oriola's Advisory Services. The new...

Indians will get the country's first dengue vaccine Qdenga next year, a key milestone to control the infectious disease that is a major public health concern for the South Asian nation....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

2026 Awardees are Corus International, Humanity & Inclusion Handicap International, Kwame Nkrumah University of Science and Technology (KNUST) and Terre des hommes Foundation (Tdh) Commitment of USD 22.2 Million Increases Takeda's Total Global CSR Program Contributions to USD 260.9 Million Across 42 Diverse Collaborations Worldwide, With 20 Currently Ongoing in 42 Countries OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company's ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company's purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting global aid priorities continue to challenge healthcare access, Takeda is advancing its 2026 collaborations with the goal of expanding equita...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Tokyo, Sept. 11 (Jiji Press)--Yasuchika Hasegawa, former president of Takeda Pharmaceutical Co. and former chairman of the Japan Association of Corporate Executives, or Keizai Doyukai, died at a Tokyo hospital July 3. He was 80. Born in Nagato, Yamaguchi Prefecture, western Japan, he joined the major drugmaker in 1970 after graduating from Waseda University. In 2003, Hasegawa took over t......

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

The partnership aims to integrate Weave Bio's AI tools with Takeda's regulatory experience to streamline workflows within the regulatory process. The joint effort began with the use of The post Takeda and Weave Bio collaborate on AI-driven automation in drug development appeared first on Pharmaceutical Business review....

TOKYO (dpa-AFX) - The U.S. Food and Drug Administration approved Takeda Pharmaceutical's (TAK, TKPHF, 4502.T) Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood ......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

This decision makes Orzeyful the only treatment in Japan currently indicated to address the underlying cause of narcolepsy type 1, also known as narcolepsy with cataplexy, rather than The post Takeda's Orzeyful secured Japan MHLW approval for narcolepsy type 1 appeared first on Pharmaceutical Business review....

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus....

The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....

Tokorozawa, Saitama Pref., Aug. 14 (Jiji Press)--Japanese manga artist Kazuyoshi Takeda, author of a series that depicts a World War II battle on the western Pacific island of Peleliu, emphasized the importance of learning about war so as not to repeat past mistakes. "For generations that have never experienced war, the first important step is to learn about it," the 50-year-old author of "......